Synthetic Derivatives of THC May Weaken HIV-1 Infection to Enhance Antiviral Therapies, Temple University Study

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

A new use for compounds related in composition to the active ingredient in marijuana may be on the horizon: a new research report published in the Journal of Leukocyte Biology shows that compounds that stimulate the cannabinoid type 2 (CB2) receptor in white blood cells, specifically macrophages, appear to weaken HIV-1 infection. The CB2 receptor is the molecular link through which the pharmaceutical properties of cannabis are manifested. Diminishing HIV-1 infection in this manner might make current anti-viral therapies more effective and provide some protection against certain HIV-1 complications.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC